SULSA’s Assay Development Fund is actively recruiting innovative molecular targets for which there is a strong rationale for therapeutic potential.
Our aim is to take your basic reagents (recombinant proteins, substrates, cell lines etc.) to develop a high quality screening assay on our robotics infrastructure. Final validation of the assay will consist of screening a well curated collection of ~7000 small molecules, comprising both known bioactives and diverse lead-like structures, to identify potential chemical starting points for drug development and to provide key information to assist in further screening and/or funding.
We will deliver the developed assay, the associated SOPs and the data back to you, along with the hit compounds.
This results from the screen will help you leverage follow on funding or provide access to the various drug discovery initiatives that are available to the academic community, i.e. MRC DPFS, Bayer G4Targets, Wellcome Trust translational fund, the European Lead Factory, AZ innovation portal etc.